PUT THE BRAKES ON PDR
Mean visual acuity letter improvement at 2 years was +2.8 in the LUCENTIS group vs +0.2 in the PRP group (p<0.001 for noninferiority) 41.8% of eyes with LUCENTIS achieved a ≥2-step DRSS improvement vs 14.6% with PRP at 1 year (p<0.001)
Clinically proven to help preserve vision compared with PRP
Improved peripheral visual field (–23 dB vs –422 dB), vitrectomy risk (4% vs 15%) and progression to DME (9% vs 28%) at 2 years (all p<0.001)
LUCENTIS has a well-established safety profile in PDR, with no new ocular or systemic safety concerns identified over 5 years of follow-up. The most common adverse events include intraocular inflammation, increased intraocular pressure, vitreous haemorrhage, eye pain and visual disturbance.
Authority required for the treatment of wet AMD, DME, BRVO, CRVO, PDR, PM or for the treatment of CNV secondary to causes other than wet AMD and PM. Refer to PBS Schedule for full Authority information. This product is not PBS listed for the treatment of ROP.
Use of this medicinal product in paediatric ROP patients is subject to additional monitoring in Australia. This will allow quick identification
For healthcare professionals only. Please review Product Information before prescribing. Scan QR code for full LUCENTIS Product Information. products/healthcare-professionals to access the full Product Information.
Results are based on the primary outcome visit at the 2-year mark in a study with follow-up through 5 years. Further data was collected and analysed through the 5-year follow-up period. Abbreviations: AMD, age-related macular degeneration; BRVO, branch retinal vein occlusion; CNV, choroidal neovascularisation; CRVO, central retinal vein occlusion; DME, diabetic macular oedema; DRSS, diabetic retinopathy severity score; HR, hazard ratio; MI, myocardial infarction; NV, neovascularisation; PBS, Pharmaceutical Benefits Scheme; PDR, proliferative diabetic retinopathy; PM, choroidal neovascularisation secondary to pathological myopia; PRP, panretinal photocoagulation; ROP, retinopathy of prematurity References: 1. LUCENTIS (ranibizumab) Australian approved Product Information. 2. Gross JG et al. JAMA. 2015; 314(20): 2137–2146 (and supplement). 3. Pharmaceutical Benefits Scheme.
Scan to find out more
Australia’s 1001 Optometry has launched a world-first tool to scan a parent’s camera phone photos for early signs of myopia in their children.
The tool, Magnif-eye, uses artificial intelligence (AI) to analyse the photos parents have stored in their camera rolls, looking for subtle indicators of undiagnosed myopia.
Importantly, Magnif-eye doesn’t store data or results. Photos are scanned on a secure Australian service and immediately discarded, without being viewed by any person, so family photos remain private, 1001 Optometry said.
Edward Lee, Retail and Optometry Director at 1001 Optometry, said the tool was developed to empower parents and promote proactive eye health and care.
“We know that every parent’s phone is a treasure trove of memories, filled with thousands of pictures of their children. That camera roll can be a powerful, preventative health tool,” he said.
“We want to start the conversation about myopia earlier and change the trajectory of children’s eye health in Australia by getting them into an optometrist’s chair sooner.”
Margaret Lam, the organisation’s Head of Optometry and Professional Services, stressed the clinical importance of early detection.
“As an optometrist, one of the most worrying trends we are seeing is the earlier onset of myopia in children. Early onset often means faster progression, which significantly increases the risk of more serious eye conditions like glaucoma, cataracts, and retinal detachment later in life,” Dr Lam explained. “This tool is a vital first step.”
